AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03676933
Drug: Hydrocortisone Butyrate 0.1% Cream
RxNorm normalized name: HYDROCORTISONE BUTYRATE 0.1% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid taken topically once a day
Trial: NCT01986660
Drug: Ibuprofen Cream (SST-0225)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01521455
Drug: HCP0910
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250/50, BID for 2 weeks
Trial: NCT04846621
Drug: Calcium channel blocker
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor
Trial: NCT01485770
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match ADX-N05 once a day for 2 consecutive weeks
Trial: NCT03035708
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg BID
Trial: NCT03779789
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-60 mg/day).
Trial: NCT02689024
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic drug: Acetanilide derivate with analgetic and antipyretic properties ATC code N02BE01
Trial: NCT02689024
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Non-Steroidal Anti-Inflammatory Drug: Acetic acid derivative ATC code M01AB05 Usual dosage is 50 mg t.i.d. orally or 75 mg b.i.d. intramuscularly. In the Netherlands, intravenous administration is not used.
Trial: NCT02689024
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE01 Usual dosage is 400 mg t.i.d. or q.i.d. orally.
Trial: NCT02689024
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE02 Usual dosage is initially 500 mg orally, followed by 250 mg b.i.d. or t.i.d.
Trial: NCT02689024
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Opioids: Phenylpiperidine derivative. Short-acting opioid. ATC code N02AB03 Usual dosage is 1 ug/kg intravenously and titrated guided by pain scores and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
Trial: NCT00811473
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment once daily in the evening
Trial: NCT03447132
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00134160
Drug: Calcium channel blockers (amlodipine, azelnidipine)
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil 20mg/Day with Calcium channel blockers (amlodipine or azelnidipine)
Trial: NCT01622361
Drug: Adriamycin+Cyclophosphamide>Docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Adriamycin 60mg/m2 + Cyclophosphamide 600mg/m2~   * Route: by slow intravenous bolus~  * Schedule: every 3weeks for 4 cycle~2. Docetaxel 75mg/m2~   * Route: intravenous as per local practice~  * Schedule: every 3weeks for 4 cycle
Trial: NCT04300114
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules po. twice daily
Trial: NCT02229747
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02229747
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02669433
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily, oral, matching tablets
Trial: NCT01868685
Drug: BYM338
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BYM338
Trial: NCT01868685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00296374
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg oral dose administered once daily for 52 weeks
Trial: NCT00296374
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg oral dose administered once daily for 4 weeks followed by 40 mg oral dose administered once daily for 48 weeks
Trial: NCT01436500
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile water with 5% Dextrose
Trial: NCT01765998
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00308282
Drug: LY2127399
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg, 60 mg or 160 mg, IV (in the vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.
Trial: NCT00308282
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV (in vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.
Trial: NCT01996449
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The subject will be started on Eplerenone (Inspra) 50-200mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued
Trial: NCT03389750
Drug: Intravenous Challenge Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of opioid drugs (oxycodone, oxymorphone, hydromorphone), for the purpose of comparison of their abuse potential among each other, and in comparison to placebo (saline).
Trial: NCT02211157
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01411371
Drug: Medical treatment alone
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment of persistent AF as 'normal care'. Patients are randomised to medical treatment alone for atrial fibrillation. Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as indicated) and rhythm control as second line (using sotalol, dronedarone, or amiodarone as indicated). (Both groups will receive standard heart failure medication including angiotensin converting enzyme inhibitors, beta blockers, aldosterone antagonists, and diuretics as indicated).
Trial: NCT02360501
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2000mg/㎡,d1-14
Trial: NCT02853578
Drug: Busonid (budesonide 200mcg and 400mcg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cartridge containing 60 tablets of 200 mcg or 400 mcg and an inhaler;~1 application (inhalation) of 200mcg every 12 noon (400 mcg / day). During the visits of monitoring (V1 and V2) the doctor in charge assess the need to increase the dose of PSI 400mcg for every 12 hours (800mcg / day); treatment for 12 weeks.
Trial: NCT02157298
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet. Oral dose
Trial: NCT03149419
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02845349
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo comparator will be used in one subset of patients.
Trial: NCT02737059
Drug: Codeine
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30mg 4 times daily
Trial: NCT02737059
Drug: codeine placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 times daily (placebo will be made to match the codeine)
Trial: NCT00133354
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.
Trial: NCT02042001
Drug: Immediate switch to TDF/FTC/RPV
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01508858
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
Trial: NCT01508858
Drug: levonorgestrel / ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single oral tablet after the liraglutide or placebo dose administration at the end of each treatment period
Trial: NCT02042001
Drug: Switch to TDF/FTC/RPV after 24 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will continue current EFV-containing regimen up to week 24 and then will be switched to TDF/FTC/RPV
Trial: NCT00615316
Drug: Guaraná
RxNorm normalized name: GUARANA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guaraná extract 75mg/day
Trial: NCT00615316
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1tab/d
Trial: NCT02676622
Drug: Preparative regimen 4-6 weeks after Leukapheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to starting medicines, a central venous line will be placed (arm or chest)~Cyclophosphamide iv: 50 mg/kg iv over 2 hours~Mesna iv (uro-protectant): 36 mg/kg iv over 12 hours~r-ATG (Thymoglobulin, Genzyme): 2.5 mg/kg/dose iv over 6 hours on days -3,-2,-1
Trial: NCT01166945
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
Trial: NCT00368849
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study utilizes a crossover design. Accordingly, half of the participants receive twice a day matching placebo at arm one while the remaining half receive this intervention at arm two.
Trial: NCT02999854
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High dose post-transplant cyclophosphamide 50 mg/kg/day at 3 and 4/5 days after the HSCT (powder for intravenous infusion)
Trial: NCT00875459
Drug: VIAject™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection 25 IU/mL
Trial: NCT02827708
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration once daily.
Trial: NCT00989014
Drug: CD07805/47
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% Topical Gel
Trial: NCT00989014
Drug: CD07805/47
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.18% Topical Gel
Trial: NCT00989014
Drug: CD07805/47
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.07% Topical Gel
Trial: NCT00989014
Drug: CD07805/47 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Topical Gel
Trial: NCT00969150
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
Trial: NCT00102102
Drug: [18F]SPA-RQ
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01654731
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04501666
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received matching placebo as SC injection.
Trial: NCT02953314
Drug: TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003150
Drug: CHOP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003150
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003150
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03925740
Drug: MI Varnish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of MI varnish material versus the standard 1.23% APF.
Trial: NCT03925740
Drug: PreviDent Varnish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of PreviDent Varnish material versus the standard 1.23% APF.
Trial: NCT03925740
Drug: 1.23% APF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 1.23% APF application
Trial: NCT00631566
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Some randomized patients will receive a placebo nasal ointment (white petroleum) and a placebo body soap with no antimicrobial activity for seven days.
Trial: NCT03387046
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks.
Trial: NCT00118794
Drug: Lumefantrine-artemether (Coartemether )
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04553536
Drug: Esketamine, Sulfentanil or/and Remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The esketamine or the opioids will be intravenously injected or infused to the patients with propofol and one of the muscle relaxants to induce and maitain general anesthesia.
Trial: NCT02184247
Drug: anhydrous theophylline, 350 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02184247
Drug: anhydrous theophylline, 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01065623
Drug: BAY79-4620
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour infusion every 14 days. Starting dose will be 0.15 mg/ kg and dose will be escalated dependent on any dose limiting toxicities
Trial: NCT00099346
Drug: MK0457, VX-680 (Aurora Kinase Inhibitor)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01272778
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule, single acute dose
Trial: NCT00245570
Drug: Comparator: Placebo (montelukast)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose matching-image placebo to montelukast tablet in two of three treatment periods
Trial: NCT00245570
Drug: Comparator: Placebo (salmeterol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose matching-image placebo of salmeterol 50 ug inhalation in two of three treatment periods
Trial: NCT03418480
Drug: BNT113
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal vaccine
Trial: NCT01991574
Drug: Calcium acetate
RxNorm normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01991574
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methylcellulose capsules
Trial: NCT00152854
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen 1g po qid
Trial: NCT00152854
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen 1g po qid for 7 days
Trial: NCT00152854
Drug: placebo, sugar pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03794323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT04264962
Drug: Yang Yin Fu Zheng Jie Du therapy
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
Trial: NCT00128947
Drug: Mycophenolic Acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00128947
Drug: Mycophenolate 7-O-Phenolic Glucuronide
RxNorm normalized name: TETRAHYDROCURCUMIN .BETA.-O-GLUCURONIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02450903
Drug: LDK378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral LDK378 750mg once daily
Trial: NCT00604539
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo capsules taken once a day for six months followed by an additional six month treatment of 800 mg (two capsules of 400 mg of Chondroitin sulphate each) taken once a day
Trial: NCT03967964
Drug: Dehydroepiandrosterone 2.2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal ring with 2.2 grams DHEA.
Trial: NCT03967964
Drug: Dehydroepiandrosterone 1.5 g/Testosterone 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal ring with DHEA 1.5 grams/Testosterone 25 mg.
Trial: NCT03967964
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal ring with 35 mg testosterone.
Trial: NCT03967964
Drug: Testosterone Topical Gel
RxNorm normalized name: Testosterone Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel containing 1% testosterone.
Trial: NCT03418974
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capsule/Tablet, oral, follow the doctor's advice Participants will receive rosuvastatin treatment for 3 or 12 weeks.
Trial: NCT00710554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
Trial: NCT00841074
Drug: Placebo mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo mouthwash spray application of \~1.3 ml twice a day.
Trial: NCT02045368
Drug: IGF-Methotrexate conjugate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle. Up to 7 dose levels will be tested, starting with 0.05 microequivalents per kg and up to 2.5 microequivalents per kg.
Trial: NCT01409564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with similar shape and color to cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, placebo 50mg bid per day will be administered orally.
Trial: NCT01036035
Drug: THVD-201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of different dosages of drug
Trial: NCT01036035
Drug: placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of different dosages of drug
Trial: NCT04615923
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration: Oral~Dose: one capsule twice daily
Trial: NCT02282020
Drug: Single agent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of relapsed disease with single agent chemotherapy based on physician's choice of weekly paclitaxel, topotecan, pegylated liposomal doxorubicin, or gemcitabine. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
Trial: NCT02244489
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine tablet(s) administered orally twice daily for 14 days, followed by 7 days off, until the end of treatment
Trial: NCT00745147
Drug: Chinese herbal formula (CCH1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: initial dose of 1.5/3.0/4.5gm herbal powder with 15/30/45ml placebo of duphalac, respectively, per day for mild/moderate/severe constipation, then titrated
Trial: NCT02561650
Drug: COV155
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COV155 tablets
Trial: NCT03518073
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT00475176
Drug: S-adenosyl methionine for Chronic Liver Disease
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03804879
Drug: Standard of Care (SoC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal tolerated doses of angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)
Trial: NCT00221754
Drug: Pravastatin (drug)
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01404390
Drug: BAY80-6946
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4mg/ kg, iv, day 1,8 and 15, every 28 days
Trial: NCT01404390
Drug: BAY80-6946
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8mg/ kg, iv, day 1,8 and 15, every 28 days
Trial: NCT01305850
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the control group will administer antihypertensive agents, except angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone. Dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg